Gold and Silver Challenging Major Resistance
Source: Jack Chan for The Gold Report��(4/30/16)
Both gold and silver are challenging major resistance while the U.S. dollar is testing support, says technical analyst Jack Chan. A break will help clarify the technical prospect going forward. More >

We Cannot Predict But We Can Prepare
Source: Jack Chan for The Energy Report��(4/30/16)
Technical analyst Jack Chan says the charts suggest that the major correction in the oil service sector since 2014 is now complete. More >

Fratboys at the Punchbowl
Source: Joe McAlinden ��(4/29/16)
The Federal Reserve, like chaperones at a fraternity house party, has appeared overly concerned about the prospect of upsetting the party-goers and has backed off from earlier indications that it would raise rates four times this year, says Joe McAlinden of McAlinden Research Partners. More >

Precious Metals Every Bit as Explosive as Secretariat at the Belmont Stakes
Source: Michael Ballanger��(4/29/16)
The charts tell the story, says precious metals expert Michael Ballanger, adding that the mining and metals market have the forward momentum of Secretariat as he clinched the Triple Crown. More >

The Two Best Calls Ever on a Gold Bottom
Source: Bob Moriarty��(4/28/16)
Bob Moriarty of 321Gold calls out the work of two men who got it right on gold and silver. More >

Let Volatility Power Your Micro-Cap Biotechs
Source: George Mack of The Life Sciences Report��(4/27/16)
ROTH Capital Partners' Joseph Pantginis falls into that old-fashioned category of analysts who believe that good data can't help but drive a stock, no matter how far into the depths it may have sunk. In this interview with The Life Sciences Report, Pantginis presents his detailed growth theory on two names, and he leaves two Focus Picks on the table for investors to do further diligence on. More >

Soligenix Fosters Potent Pipeline of Orphan Disease Compounds in Areas of Unmet Medical Need
Source: Special to The Life Sciences Report��(4/27/16)
With a robust pipeline of drugs in late-stage clinical trials and milestones on the horizon, it's no wonder Soligenix Inc.'s CEO, Dr. Christopher Schaber, holds an optimistic view of the company's future. Two candidates targeting orphan diseases—a type of lymphoma and pediatric Crohn's disease—are in Phase 3, a treatment for oral mucositis is in Phase 2, and Soligenix's biodefense vaccine and therapeutic platform is backed by significant government funding. In this interview with The Life Sciences Report, Dr. Schaber expands on the status of the company's portfolio. More >

What Steve Jobs Knew About the Internet Can Make You a Better Gold Investor
Source: Bob Moriarty��(4/27/16)
Of all the people in the tech world, Steve Jobs perhaps understood the potential of the Internet better than any of his peers. Bob Moriarty of 321Gold discusses how Jobs' insight can provide lessons on gold manipulation and what moves markets. More >

The Significance of Rising Commodities Prices…
Source: Michael Ballanger��(4/27/16)
Precious metals expert Michael Ballanger expounds on how Federal Reserve policy affects the commodities markets, and expresses cautious optimism about how that policy will play out in gold markets. More >

Back-to-Back Good News for Nevada Energy Metals
Source: Keith Kohl ��(4/27/16)
Not long after Nevada Energy Metals expanded its presence in the Clayton Valley, the company announced it added claims to its San Emidio property. Keith Kohl of Oil & Gas Trader explains what this means to investors. More >

Mining M&A Warming Up with Reservoir and Sunridge Deals
Source: Adrian Day��(4/27/16)
Adrian Day shares additional thoughts on Nevsun's deal to buy Reservoir Minerals. The investment conclusion—to hold—remains. And he has an update on Sunridge being acquired. More >

Low Prices for Oil Cure Low Prices for Oil
Source: Bob Moriarty��(4/27/16)
Veteran investor Bob Moriarty discusses one company that is poised to benefit from the volatililty in the oil markets. More >

Are We or Are We Not in a New Gold Bull Market?
Source: Jack Chan for The Gold Report��(4/26/16)
Technical analyst Jack Chan has examined the charts and says that if we are in a new bull market, prices in both gold and gold equities should begin to pull back and consolidate soon. More >

LiTHIUM X Is Not Alone—Profiling This Marketplace Darling and Others in the Sweet Spot
Source: Patrice Fusillo of The Gold Report��(4/25/16)
After several years of bear markets for miners, many mining equities have lept upward in the last few months. LiTHIUM X Energy ranks among the leaders of the pack, up many-fold. Barry Allan, vice chair of mining at Mackie Research, and Research Analyst Ryan Hanley put out a report in March for the PDAC convention, highlighting a number of promising mining companies. In this interview with The Gold Report, Allan and Hanley profile a handful of those companies, including LiTHIUM X. More >

Hold Reservoir Minerals After Takeout: Adrian Day
Source: Adrian Day��(4/24/16)
On Sunday, Reservoir Minerals announced it has agreed to be acquired by Nevsun Resources. Adrian Day shares his initial thoughts on the deal. More >

Madness in the Crimex Trading Pits. . .
Source: Michael Ballanger��(4/22/16)
Precious metals expert Michael Ballanger discusses effects of the Bank of Japan's actions on the U.S. dollar, silver and gold. More >

President Trump? President Clinton? Gold Up in Both Scenarios
Source: Gordon Holmes of The Gold Report��(4/21/16)
Donald Trump and Hillary Clinton may have very little in common, but Barry Allan, vice chair of mining for Mackie Research Capital, says if either moves into the White House, the U.S. dollar will fall and gold will rise. A higher gold price bodes well for gold equities, and in this interview with The Gold Report, Allan and his colleague Ryan Hanley share the names of some of their top picks for this environment.
More >

What Andy Grove and Michael Milken Have Taught Us About Prostate Cancer
Source: George S. Mack of The Life Sciences Report ��(4/20/16)
Solid tumors are typically managed with surgical resection, chemotherapy, radiation and biologics, but it's the secondary tumor mass, the metastasis, that kills patients. Dr. Stuart Holden of the UCLA Institute of Urologic Oncology understands the importance of targeting metastatic disease, which is driven by different genetic factors than the primary tumor from which it arose—a fact that oncologists are just now coming to grips with. In this interview with The Life Sciences Report, Dr. Holden describes an essential target in aggressive prostate cancers, and a drug with the potential to address that target and extend the lives of thousands of men. More >

Relmada Therapeutics Launches Pharmaceutical Armada Against Chronic Pain and Opioid Abuse
Source: Special to The Life Sciences Report��(4/20/16)
To treat chronic pain without risk of addiction is to straddle a knife's edge. But Relmada Therapeutics Inc. has a small fleet of compounds in development that address both sides of an issue that has become a newsmaker, given the recent upsurge in heroin addiction and the ever-present conundrum of alleviating severe pain in chronic disease and after surgery. In this interview with The Life Sciences Report, Relmada's Michael Becker describes the company's programs, which are advancing steadily toward the marketplace.
More >

All Hail the Mighty Silver Bugs…
Source: Michael Ballanger��(4/20/16)
Precious metals expert Michael Ballanger examines silver's recent moves upward. More >

Looming Zinc Supply Shortage Good News for Producers and Explorers: Stefan Ioannou
Source: Patrice Fusillo of The Gold Report��(4/18/16)
The outlook for zinc appears bullish, says Stefan Ioannou of Haywood Securities, spearheaded by mine closures, dwindling production and the dearth of replacement projects. This looming supply gap could mean increased zinc prices by the end of the year, explains Ioannou in this interview with The Gold Report, a prospect that would bode well for one of the few pure-play zinc producers, as well as for an Australian explorer that may be on the cusp of a world-class discovery. More >

Gold Trading Model and COT Data Are in Conflict
Source: Jack Chan��(4/18/16)
Technical Analyst Jack Chan says his trading model is indicating that the gold sector is on a new major buy signal, but the COT data is bearish, so he is waiting for the COT to return to bull market values. More >

COT Report for the Week Ended April 12: Commercial Signal Failure Looms?
Source: Michael Ballanger��(4/17/16)
Precious metals expert Michael Ballanger dissects Friday's COT report. More >

The Canadian Shield Could Host the Next Bonanza Discovery: Eric Lemieux
Source: Patrice Fusillo of The Gold Report��(4/14/16)
Gold supply is getting tighter, deposits of quality are getting rarer and the project development timeline is getting longer. Enter Canada. The Canadian Shield still offers the possibility of break-out discoveries, says PearTree Securities analyst Eric Lemieux. The recent spate of M&A activity points to the potential of the region, and Lemieux discusses several companies that are well positioned to add value. More >

Deutsche Bank Silver Settlement: GATA Vindicated
Source: Michael Ballanger��(4/14/16)
Precious metals expert Michael Ballanger riffs on the news that Deutsche Bank is settling U.S. silver pricing litigation. More >